Quoin: Positive Phase 2/3 interim data for QRX003 in Netherton Syndrome

 

Positive Phase 2/3 interim data for QRX003 in Netherton Syndrome sparks 42% premarket surge

• Quoin reported positive interim data from ongoing Phase 2/3 study of QRX003; first six patients completing 12 weeks met pre-specified alpha-adjusted primary endpoint with statistical significance.
• Data release coincided with announcement of up to $50M private placement financing, providing substantial runway for pivotal studies and commercialization efforts.
• Stock closed Aug 27 at $5.16 then jumped to ~$7.26 in extended trading (+40.8%), matching the reported 42.19% pre-market move on Aug 28.
• QRX003, a topical serine protease inhibitor using Invisicare technology, targets rare dermatologic disease Netherton Syndrome with no approved therapies.
• Prior updates included FDA conditional brand name approval (QYLEKI™), IND clearance for Peeling Skin Syndrome expansion, and positive compassionate-use pediatric results from June 2026.
• Company had ~$10.8M in cash post-Q2 2026; new capital expected to fund operations into 2027 and support Phase 3 initiation in Netherton Syndrome.
• Small-cap biotech (prior market cap ~$10M) reacted sharply to first statistically significant efficacy signal in pivotal-path study.

https://finviz.com/stock?t=QNRX&p=d